New Message from President
Seikagaku Initiates Phase II Study of SI-613 for Treatment of Knee Osteoarthritis in the U.S.
Presentation Material for the Briefing on FY2016 Financial Results
Consolidated Financial Results for Fiscal 2016 (Year Ended March 31, 2017)
Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan